The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy

Gordon Mills, Yiling Lu, Xianjun Fang, Hongwei Wang, Astrid Eder, Muling Mao, Ramona Swaby, Kwai Wa Cheng, David Stokoe, Kathy Siminovitch, Robert Jaffe, Joe Gray

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Breast and ovarian cancers exhibit similar epidemiologic, genotypic, and phenotypic characteristics. Phosphatidylinositol 3-kinase (P13K) and the PTEN tumor suppressor gene product phosphorylate and dephosphorylate the same 3′ site in the inositol ring of membrane phosphatidylinositols. Germ-line mutations in the PTEN tumor suppressor gene are causative of Cowden's breast cancer predisposition syndrome, and PTEN is frequently mutated in sporadic breast cancers. In contrast, amplification of multiple components of the P13K pathway is a hallmark of serous epithelial ovarian cancers. The resultant activation of the P13K pathway in both breast and ovarian cancers contributes to cell-cycle progression, decreased apoptosis, and increased metastatic capabilities. Strikingly, both ovarian and breast cancer cells are selectively sensitive to pharmacologic and genetic manipulation of the P13K pathway, making molecular therapeutics targeting this pathway particularly attractive approaches for these cancers.

Original languageEnglish (US)
Pages (from-to)125-141
Number of pages17
JournalSeminars in Oncology
Volume28
Issue number5 SUPPL. 16
StatePublished - 2001
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Carcinogenesis
Breast
Breast Neoplasms
Ovarian Neoplasms
Tumor Suppressor Genes
Therapeutics
Germ-Line Mutation
Inositol
Phosphatidylinositols
Cell Cycle
Apoptosis
Membranes
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. / Mills, Gordon; Lu, Yiling; Fang, Xianjun; Wang, Hongwei; Eder, Astrid; Mao, Muling; Swaby, Ramona; Cheng, Kwai Wa; Stokoe, David; Siminovitch, Kathy; Jaffe, Robert; Gray, Joe.

In: Seminars in Oncology, Vol. 28, No. 5 SUPPL. 16, 2001, p. 125-141.

Research output: Contribution to journalArticle

Mills, G, Lu, Y, Fang, X, Wang, H, Eder, A, Mao, M, Swaby, R, Cheng, KW, Stokoe, D, Siminovitch, K, Jaffe, R & Gray, J 2001, 'The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy', Seminars in Oncology, vol. 28, no. 5 SUPPL. 16, pp. 125-141.
Mills, Gordon ; Lu, Yiling ; Fang, Xianjun ; Wang, Hongwei ; Eder, Astrid ; Mao, Muling ; Swaby, Ramona ; Cheng, Kwai Wa ; Stokoe, David ; Siminovitch, Kathy ; Jaffe, Robert ; Gray, Joe. / The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. In: Seminars in Oncology. 2001 ; Vol. 28, No. 5 SUPPL. 16. pp. 125-141.
@article{a41376bd7f484aaeb116a1dbdc667d71,
title = "The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy",
abstract = "Breast and ovarian cancers exhibit similar epidemiologic, genotypic, and phenotypic characteristics. Phosphatidylinositol 3-kinase (P13K) and the PTEN tumor suppressor gene product phosphorylate and dephosphorylate the same 3′ site in the inositol ring of membrane phosphatidylinositols. Germ-line mutations in the PTEN tumor suppressor gene are causative of Cowden's breast cancer predisposition syndrome, and PTEN is frequently mutated in sporadic breast cancers. In contrast, amplification of multiple components of the P13K pathway is a hallmark of serous epithelial ovarian cancers. The resultant activation of the P13K pathway in both breast and ovarian cancers contributes to cell-cycle progression, decreased apoptosis, and increased metastatic capabilities. Strikingly, both ovarian and breast cancer cells are selectively sensitive to pharmacologic and genetic manipulation of the P13K pathway, making molecular therapeutics targeting this pathway particularly attractive approaches for these cancers.",
author = "Gordon Mills and Yiling Lu and Xianjun Fang and Hongwei Wang and Astrid Eder and Muling Mao and Ramona Swaby and Cheng, {Kwai Wa} and David Stokoe and Kathy Siminovitch and Robert Jaffe and Joe Gray",
year = "2001",
language = "English (US)",
volume = "28",
pages = "125--141",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 16",

}

TY - JOUR

T1 - The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy

AU - Mills, Gordon

AU - Lu, Yiling

AU - Fang, Xianjun

AU - Wang, Hongwei

AU - Eder, Astrid

AU - Mao, Muling

AU - Swaby, Ramona

AU - Cheng, Kwai Wa

AU - Stokoe, David

AU - Siminovitch, Kathy

AU - Jaffe, Robert

AU - Gray, Joe

PY - 2001

Y1 - 2001

N2 - Breast and ovarian cancers exhibit similar epidemiologic, genotypic, and phenotypic characteristics. Phosphatidylinositol 3-kinase (P13K) and the PTEN tumor suppressor gene product phosphorylate and dephosphorylate the same 3′ site in the inositol ring of membrane phosphatidylinositols. Germ-line mutations in the PTEN tumor suppressor gene are causative of Cowden's breast cancer predisposition syndrome, and PTEN is frequently mutated in sporadic breast cancers. In contrast, amplification of multiple components of the P13K pathway is a hallmark of serous epithelial ovarian cancers. The resultant activation of the P13K pathway in both breast and ovarian cancers contributes to cell-cycle progression, decreased apoptosis, and increased metastatic capabilities. Strikingly, both ovarian and breast cancer cells are selectively sensitive to pharmacologic and genetic manipulation of the P13K pathway, making molecular therapeutics targeting this pathway particularly attractive approaches for these cancers.

AB - Breast and ovarian cancers exhibit similar epidemiologic, genotypic, and phenotypic characteristics. Phosphatidylinositol 3-kinase (P13K) and the PTEN tumor suppressor gene product phosphorylate and dephosphorylate the same 3′ site in the inositol ring of membrane phosphatidylinositols. Germ-line mutations in the PTEN tumor suppressor gene are causative of Cowden's breast cancer predisposition syndrome, and PTEN is frequently mutated in sporadic breast cancers. In contrast, amplification of multiple components of the P13K pathway is a hallmark of serous epithelial ovarian cancers. The resultant activation of the P13K pathway in both breast and ovarian cancers contributes to cell-cycle progression, decreased apoptosis, and increased metastatic capabilities. Strikingly, both ovarian and breast cancer cells are selectively sensitive to pharmacologic and genetic manipulation of the P13K pathway, making molecular therapeutics targeting this pathway particularly attractive approaches for these cancers.

UR - http://www.scopus.com/inward/record.url?scp=0035168724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035168724&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 125

EP - 141

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 16

ER -